Telescope Innovations Corp. (TELIF)
USD 0.2
(2.36%)
USD 0.2
(2.36%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -725.38 Thousand CAD | 87.42% |
| 2022 | -5.76 Million CAD | -43.38% |
| 2021 | -4.02 Million CAD | -1489.82% |
| 2020 | -252.97 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 267.95 Thousand CAD | 151.91% |
| 2023 Q2 | 3911.00 CAD | 101.32% |
| 2023 Q1 | -295.6 Thousand CAD | 61.62% |
| 2023 FY | -725.38 Thousand CAD | 87.42% |
| 2023 Q4 | -516.23 Thousand CAD | -725.38% |
| 2023 Q3 | 82.54 Thousand CAD | 2010.66% |
| 2022 Q4 | -770.2 Thousand CAD | 22.21% |
| 2022 Q3 | -990.14 Thousand CAD | 69.19% |
| 2022 Q2 | -3.21 Million CAD | -305.64% |
| 2022 Q1 | -792.34 Thousand CAD | -43.71% |
| 2022 FY | -5.76 Million CAD | -43.38% |
| 2021 Q3 | -3.29 Million CAD | -2142.43% |
| 2021 FY | -4.02 Million CAD | -1489.82% |
| 2021 Q4 | -551.35 Thousand CAD | 83.27% |
| 2021 Q2 | 161.36 Thousand CAD | 522.29% |
| 2021 Q1 | -38.21 Thousand CAD | -15.63% |
| 2020 Q4 | -33.04 Thousand CAD | 0.0% |
| 2020 Q2 | -33.06 Thousand CAD | 0.0% |
| 2020 FY | -252.97 Thousand CAD | 0.0% |
| 2019 Q4 | -33.24 Thousand CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bioxytran, Inc. | -3.82 Million USD | 81.012% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 98.99% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -177.153% |
| SQZ Biotechnologies Company | -75.82 Million USD | 99.043% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 74.553% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 95.936% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.886% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 52.776% |
| Marizyme, Inc. | -34.08 Million USD | 97.872% |
| Genus plc | 6.4 Million USD | 111.334% |
| Pharming Group N.V. | -4.87 Million USD | 85.134% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 63.484% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 22.118% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 91.313% |
| ContraFect Corporation | -56.88 Million USD | 98.725% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 48.261% |
| IMV Inc. | -38.67 Million USD | 98.124% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 73.631% |
| ONE Bio Corp. | 13.68 Million USD | 105.302% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 98.77% |
| Mesoblast Limited | -84.14 Million USD | 99.138% |
| MultiCell Technologies, Inc. | -722.81 USD | -100255.833% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 120.491% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.826% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -86.201% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 72.393% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 114.759% |
| Biomind Labs Inc. | -1 Million USD | 28.152% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 74.998% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 89.089% |
| Skye Bioscience, Inc. | -13.67 Million USD | 94.694% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 61.092% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 107.446% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -2321.815% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 84.074% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 85.62% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 95.429% |
| Accustem Sciences Inc. | -3.74 Million USD | 80.638% |
| EV Biologics, Inc. | -483.06 Thousand USD | -50.163% |
| Q BioMed Inc. | -3.44 Million USD | 78.948% |
| GB Sciences, Inc. | -1.42 Million USD | 48.935% |
| Alpha Cognition Inc. | -9.7 Million USD | 92.526% |
| CSL Limited | 3.7 Billion USD | 100.02% |
| Agentix Corp. | -1.37 Million USD | 47.12% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 98.68% |
| Enzolytics Inc. | -2.14 Million USD | 66.242% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | -12.74 Million USD | 94.31% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 77.105% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 62.466% |
| argenx SE | -425.04 Million USD | 99.829% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 98.693% |
| HST Global, Inc. | -140.9 Thousand USD | -414.795% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 30.519% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 35.516% |
| Halberd Corporation | -75.05 Thousand USD | -866.532% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 75.153% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 78.696% |
| Zenith Capital Corp. | -8.94 Million USD | 91.889% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 54.071% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 70.457% |
| AVAX Technologies, Inc. | 6.69 Million USD | 110.838% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -322.94% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 63.817% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -4063.837% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -2.46 Million USD | 70.594% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 26.286% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 42.247% |
| Kadimastem Ltd | -3.04 Million USD | 76.141% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | 90.675% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -299.693% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 45.682% |
| LadRx Corporation | -3.82 Million USD | 81.029% |
| Cell Source, Inc. | -4.32 Million USD | 83.23% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -74.589% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -5.595% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -5.595% |
| Affymax, Inc. | -15.04 Million USD | 95.179% |
| Mobile Lads Corp. | -554.55 Thousand USD | -30.806% |
| Itoco Inc. | -919.14 Thousand USD | 21.08% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 82.886% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 35.176% |
| International Stem Cell Corporation | -663 Thousand USD | -9.409% |
| CytoDyn Inc. | -18.05 Million USD | 95.983% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -2781.931% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -229.602% |
| Qrons Inc. | -643.67 Thousand USD | -12.693% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -28.449% |
| SYBLEU INC | -149.18 Thousand USD | -386.246% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | 67.47% |
| Rebus Holdings, Inc. | -664 Thousand USD | -9.244% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 60.063% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -1278.005% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -3466.283% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 98.0% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 55.168% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 1.421% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 76.683% |
| Neutra Corp. | -229.48 Thousand USD | -216.09% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 95.864% |
| PureTech Health plc | -146.19 Million USD | 99.504% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 96.625% |
| IXICO plc | -1.43 Million USD | 49.521% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 92.357% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.404% |
| CSL Limited | 3.81 Billion USD | 100.019% |
| Cellectis S.A. | -108.85 Million USD | 99.334% |